{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:48:59Z","timestamp":1785383339402,"version":"3.55.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012287","name":"Andrew Sabin Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012287","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.hfc.2022.02.011","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T19:20:03Z","timestamp":1655407203000},"page":"361-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Myocardial Dysfunction in Patients with Cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"Efstratios","family":"Koutroumpakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas L.","family":"Palaskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezar","family":"Iliescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Wamique","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hfc.2022.02.011_bib1","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.011_bib2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"11_Supplement","key":"10.1016\/j.hfc.2022.02.011_bib3","doi-asserted-by":"crossref","first-page":"A695","DOI":"10.1016\/S0735-1097(18)31236-1","article-title":"Short and long term risk of congestive heart failure in breast cancer and lymphoma patients compared to controls: an epidemiologic study","volume":"71","author":"Larsen","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hfc.2022.02.011_bib4","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.hfc.2022.02.011_bib5","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.hfc.2022.02.011_bib6","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1161\/CIRCULATIONAHA.112.000790","article-title":"Tumors metastatic to the heart","volume":"128","author":"Goldberg","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.011_bib7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/1076029613481844","article-title":"Venous thromboembolism in hospitalized patients with active cancer","volume":"19","author":"Piazza","year":"2013","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.011_bib8","first-page":"89","article-title":"Mechanism and management of cancer-associated thrombosis","volume":"72","author":"Mukai","year":"2018","journal-title":"J\u00a0Cardiol"},{"issue":"25 Suppl","key":"10.1016\/j.hfc.2022.02.011_bib9","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.hfc.2022.02.011_bib10","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","article-title":"Clinician's guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week","volume":"72","author":"Ridker","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.011_bib11","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1002\/ehf2.13647","article-title":"Stress cardiomyopathy in hospitalized patients with cancer: machine learning analysis by primary malignancy type","volume":"8","author":"Javaid","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"7","key":"10.1016\/j.hfc.2022.02.011_bib12","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1161\/CIRCULATIONAHA.118.033603","article-title":"Linking heart failure to cancer: background evidence and research perspectives","volume":"138","author":"Bertero","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.011_bib13","doi-asserted-by":"crossref","first-page":"e002661","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"10","key":"10.1016\/j.hfc.2022.02.011_bib14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2022.02.011_bib15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.011_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaccao.2020.02.016","article-title":"Longitudinal changes in echocardiographic parameters of cardiac function in pediatric cancer survivors","volume":"2","author":"Border","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.011_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0149-2918(00)88288-0","article-title":"Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer","volume":"21","author":"Goldenberg","year":"1999","journal-title":"Clin Ther"},{"issue":"16","key":"10.1016\/j.hfc.2022.02.011_bib18","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.hfc.2022.02.011_bib19","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.011_bib20","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1080\/21645515.2015.1125056","article-title":"Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline type I from type II cardiomyopathies?","volume":"12","author":"Riccio","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.hfc.2022.02.011_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fphar.2014.00025","article-title":"The role of iron in anthracycline cardiotoxicity","volume":"5","author":"Gammella","year":"2014","journal-title":"Front Pharmacol"},{"issue":"22","key":"10.1016\/j.hfc.2022.02.011_bib22","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.011_bib23","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/annonc\/mdw671","article-title":"Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis","volume":"28","author":"Abdel-Qadir","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hfc.2022.02.011_bib24","doi-asserted-by":"crossref","first-page":"594123","DOI":"10.3389\/fcvm.2020.594123","article-title":"Topoisomerase 2B decrease results in diastolic dysfunction via p53 and Akt: a novel pathway","volume":"7","author":"Moudgil","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.011_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem Biol"},{"issue":"11","key":"10.1016\/j.hfc.2022.02.011_bib26","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"issue":"31","key":"10.1016\/j.hfc.2022.02.011_bib27","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hfc.2022.02.011_bib28","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2022.02.011_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/1179546819866445","article-title":"Cancer therapy-related cardiac dysfunction: an overview for the clinician","volume":"13","author":"Perez","year":"2019","journal-title":"Clin Med Insights Cardiol"},{"issue":"10","key":"10.1016\/j.hfc.2022.02.011_bib30","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1161\/CIRCRESAHA.112.267286","article-title":"Neuregulin in cardiovascular development and disease","volume":"111","author":"Odiete","year":"2012","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.011_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcard.2010.03.003","article-title":"Cardiac side-effects of cancer chemotherapy","volume":"144","author":"Monsuez","year":"2010","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.011_bib32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.hfc.2022.02.011_bib33","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.3389\/fphar.2019.01531","article-title":"Doxorubicin induces endotheliotoxicity and mitochondrial dysfunction via ROS\/eNOS\/NO pathway","volume":"10","author":"He","year":"2019","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.011_bib34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12885-020-06868-4","article-title":"Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer","volume":"20","author":"Bloom","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.011_bib35","first-page":"1147","article-title":"Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer","volume":"34","author":"Sandoo","year":"2014","journal-title":"Anticancer Res"},{"issue":"20","key":"10.1016\/j.hfc.2022.02.011_bib36","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","article-title":"Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)","volume":"32","author":"de Azambuja","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.011_bib37","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.18632\/oncotarget.23543","article-title":"Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity","volume":"9","author":"Jiang","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.hfc.2022.02.011_bib38","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.hfc.2022.02.011_bib39","first-page":"Cd006243","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"2012","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"10.1016\/j.hfc.2022.02.011_bib40","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1200\/JCO.2014.60.1799","article-title":"Update on metastatic gastric and esophageal cancers","volume":"33","author":"Shah","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.hfc.2022.02.011_bib41","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.011_bib42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdr294","article-title":"Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab","volume":"23","author":"Lenihan","year":"2012","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hfc.2022.02.011_bib43","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","article-title":"Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and\/or Trastuzumab treatment optimization trial","volume":"34","author":"Piccart-Gebhart","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.hfc.2022.02.011_bib44","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"15","key":"10.1016\/j.hfc.2022.02.011_bib45","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.011_bib46","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.011_bib47","doi-asserted-by":"crossref","first-page":"C1358","DOI":"10.1152\/ajpcell.2001.280.6.C1358","article-title":"Role of vascular endothelial growth factor in regulation of physiological angiogenesis","volume":"280","author":"Ferrara","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.hfc.2022.02.011_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coph.2014.11.010","article-title":"Etiology of angiogenesis inhibition-related hypertension","volume":"21","author":"Lankhorst","year":"2015","journal-title":"Curr Opin Pharmacol"},{"issue":"9","key":"10.1016\/j.hfc.2022.02.011_bib49","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11936-014-0335-0","article-title":"Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway","volume":"16","author":"Groarke","year":"2014","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.011_bib50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s13273-018-0027-z","article-title":"Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy","volume":"14","author":"Lee","year":"2018","journal-title":"Mol Cell Toxicol"},{"issue":"14","key":"10.1016\/j.hfc.2022.02.011_bib51","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1158\/1078-0432.CCR-16-2869","article-title":"Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma","volume":"23","author":"Narayan","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9604","key":"10.1016\/j.hfc.2022.02.011_bib52","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.hfc.2022.02.011_bib53","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1200\/JCO.2010.34.4309","article-title":"Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib","volume":"29","author":"Richards","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.011_bib54","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hfc.2022.02.011_bib55","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.2147\/OTT.S170138","article-title":"Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities","volume":"11","author":"Chaar","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.011_bib56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.011_bib57","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.011_bib58","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat Med"},{"issue":"35","key":"10.1016\/j.hfc.2022.02.011_bib59","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.011_bib60","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate","volume":"14","author":"Brave","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hfc.2022.02.011_bib61","doi-asserted-by":"crossref","first-page":"102282","DOI":"10.1016\/j.ctrv.2021.102282","article-title":"Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors","volume":"100","author":"Arangalage","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.011_bib62","doi-asserted-by":"crossref","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: A systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.011_bib63","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A\u00a0decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.hfc.2022.02.011_bib64","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysisfatal toxic effects associated with immune checkpoint inhibitorsfatal toxic effects associated with immune checkpoint inhibitors","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.hfc.2022.02.011_bib65","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.hfc.2022.02.011_bib66","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ejhf.2265","article-title":"Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"10.1016\/j.hfc.2022.02.011_bib67","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hfc.2022.02.011_bib68","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.011_bib69","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A\u00a0genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"issue":"15","key":"10.1016\/j.hfc.2022.02.011_bib70","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1158\/1078-0432.CCR-18-4083","article-title":"Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors","volume":"25","author":"Ji","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hfc.2022.02.011_bib71","doi-asserted-by":"crossref","first-page":"107211","DOI":"10.1016\/j.carpath.2020.107211","article-title":"Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: pathway toward precision-based therapy","volume":"47","author":"Balanescu","year":"2020","journal-title":"Cardiovasc Pathol"},{"issue":"16","key":"10.1016\/j.hfc.2022.02.011_bib72","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.011_bib73","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2022.02.011_bib74","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.011_bib75","article-title":"Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management","volume":"1","author":"Dhesi","year":"2013","journal-title":"J\u00a0Investig Med High Impact Case Rep"},{"issue":"4","key":"10.1016\/j.hfc.2022.02.011_bib76","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1440-1681.2009.05323.x","article-title":"Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress","volume":"37","author":"Ma","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.hfc.2022.02.011_bib77","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tox.2016.10.001","article-title":"An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures","volume":"371","author":"Dugbartey","year":"2016","journal-title":"Toxicology"},{"issue":"28","key":"10.1016\/j.hfc.2022.02.011_bib78","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1200\/JCO.2014.60.3654","article-title":"Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study","volume":"33","author":"Fung","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.hfc.2022.02.011_bib79","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1016\/j.bmc.2014.02.035","article-title":"Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function","volume":"22","author":"Field","year":"2014","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"10.1016\/j.hfc.2022.02.011_bib80","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1008309916974","article-title":"Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin","volume":"10","author":"Colombo","year":"1999","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.011_bib81","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"issue":"13","key":"10.1016\/j.hfc.2022.02.011_bib82","first-page":"3028","article-title":"In\u00a0vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle","volume":"53","author":"Mosseri","year":"1993","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.011_bib83","first-page":"22","article-title":"Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study","volume":"38","author":"Peng","year":"2018","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.011_bib84","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.011_bib85","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.011_bib86","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/CRD.0000000000000183","article-title":"Cardiovascular complications of proteasome inhibitors used in multiple myeloma","volume":"26","author":"Cole","year":"2018","journal-title":"Cardiol Rev"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.011_bib87","doi-asserted-by":"crossref","first-page":"e87671","DOI":"10.1371\/journal.pone.0087671","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.011_bib88","doi-asserted-by":"crossref","first-page":"28982","DOI":"10.3402\/jchimp.v5.28982","article-title":"Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy","volume":"5","author":"Meseeha","year":"2015","journal-title":"J\u00a0Community Hosp Intern Med Perspect"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.011_bib89","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.011_bib90","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6524","key":"10.1016\/j.hfc.2022.02.011_bib91","doi-asserted-by":"crossref","first-page":"eabb0738","DOI":"10.1126\/science.abb0738","article-title":"Clocks, cancer, and chronochemotherapy","volume":"371","author":"Sancar","year":"2021","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.hfc.2022.02.011_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102168","article-title":"Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy","volume":"18","author":"Ozturk","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.011_bib93","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2016.03.004","article-title":"Dosing-time makes the poison: circadian regulation and pharmacotherapy","volume":"22","author":"Dallmann","year":"2016","journal-title":"Trends Mol Med"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.011_bib94","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.011_bib95","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"36","key":"10.1016\/j.hfc.2022.02.011_bib96","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.hfc.2022.02.011_bib97","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.011_bib100","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.hfc.2022.02.011_bib101","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hfc.2022.02.011_bib102","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.011_bib103","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0002-9343(87)90212-9","article-title":"Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography","volume":"82","author":"Schwartz","year":"1987","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.011_bib104","doi-asserted-by":"crossref","first-page":"e000472","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"18","key":"10.1016\/j.hfc.2022.02.011_bib105","doi-asserted-by":"crossref","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the american and european cardio-oncology guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J\u00a0Am Heart Assoc"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713622000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713622000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:41:36Z","timestamp":1761554496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713622000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1551713622000125"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2022.02.011","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myocardial Dysfunction in Patients with Cancer","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2022.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}